{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:14:16Z","timestamp":1790162056227,"version":"4.1.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04396-4","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T19:26:45Z","timestamp":1779046005000},"page":"4575-4596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Elena A.","family":"Nemilostiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-3992","authenticated-orcid":false,"given":"Olga A.","family":"Paevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxrat","family":"Boymuradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baqodir","family":"Safoyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirmukhsin","family":"Satov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"4396_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials. Biomed Pharmacother. 2023;169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4396_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02928-6","volume":"42","author":"YA Albalawi","year":"2025","unstructured":"Albalawi YA. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. Med Oncol. 2025;42(9):378. https:\/\/doi.org\/10.1007\/s12032-025-02928-6.","journal-title":"Med Oncol"},{"key":"4396_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1511931","volume":"12","author":"F Dehghan","year":"2025","unstructured":"Dehghan F, Metanat Y, Askarizadeh M, et al. Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy. Front Cell Dev Biol. 2025;12:1511931. https:\/\/doi.org\/10.3389\/fcell.2024.1511931.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4396_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4396_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4396_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, et al. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14(1):66. https:\/\/doi.org\/10.1186\/s40164-025-00654-3.","journal-title":"Exp Hematol Oncol"},{"key":"4396_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291619","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Xu Q, Gao Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front Immunol. 2023;14:1291619. https:\/\/doi.org\/10.3389\/fimmu.2023.1291619.","journal-title":"Front Immunol"},{"issue":"1","key":"4396_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23(1):86. https:\/\/doi.org\/10.1186\/s12935-023-02923-9.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4396_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.161.1.375","volume":"161","author":"MR Roberts","year":"1998","unstructured":"Roberts MR, Cooke KS, Tran A-C, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing \u03b6 or \u03b3 signaling domains. J Immunol. 1998;161(1):375\u201384.","journal-title":"J Immunol"},{"issue":"1","key":"4396_CR10","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14(1):2266.","journal-title":"Nat Commun"},{"key":"4396_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2024.103106","volume":"87","author":"A L\u00f3pez-Arredondo","year":"2024","unstructured":"L\u00f3pez-Arredondo A, Cruz-Cardenas JA, C\u00e1zares-Preciado JA, et al. Neutrophils, an emerging new therapeutic platform. Curr Opin Biotechnol. 2024;87:103106. https:\/\/doi.org\/10.1016\/j.copbio.2024.103106.","journal-title":"Curr Opin Biotechnol"},{"issue":"6","key":"4396_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.stemcr.2019.10.007","volume":"13","author":"VS Brok-Volchanskaya","year":"2019","unstructured":"Brok-Volchanskaya VS, Bennin DA, Suknuntha K, et al. Effective and rapid generation of functional neutrophils from induced pluripotent stem cells using ETV2-Modified mRNA. Stem Cell Reports. 2019;13(6):1099\u2013110. https:\/\/doi.org\/10.1016\/j.stemcr.2019.10.007.","journal-title":"Stem Cell Reports"},{"issue":"2","key":"4396_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","volume":"99","author":"PX Liew","year":"2019","unstructured":"Liew PX, Kubes P. The neutrophil\u2019s role during health and disease. Physiol Rev. 2019;99(2):1223\u201348.","journal-title":"Physiol Rev"},{"issue":"6","key":"4396_CR14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00011-023-01737-9","volume":"72","author":"K Ganesh","year":"2023","unstructured":"Ganesh K, Joshi MB. Neutrophil sub-types in maintaining immune homeostasis during steady state, infections and sterile inflammation. Inflamm Res. 2023;72(6):1175\u201392.","journal-title":"Inflamm Res"},{"issue":"3","key":"4396_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173\u201387.","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"4396_CR16","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","volume":"23","author":"HL Matlung","year":"2018","unstructured":"Matlung HL, Babes L, Zhao XW, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946-59.e6. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.082.","journal-title":"Cell Rep"},{"issue":"3","key":"4396_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030694","volume":"13","author":"F Ren\u00f2","year":"2025","unstructured":"Ren\u00f2 F, Pagano CA, Bignotto M, et al. Neutrophil heterogeneity in wound healing. Biomedicines. 2025;13(3):0694. https:\/\/doi.org\/10.3390\/biomedicines13030694.","journal-title":"Biomedicines"},{"issue":"6","key":"4396_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063218","volume":"23","author":"S Raftopoulou","year":"2022","unstructured":"Raftopoulou S, Valadez-Cosmes P, Mihalic ZN, et al. Tumor-mediated neutrophil polarization and therapeutic implications. Int J Mol Sci. 2022;23(6):3218. https:\/\/doi.org\/10.3390\/ijms23063218.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4396_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4049\/jimmunol.2200154","volume":"209","author":"G Wigerblad","year":"2022","unstructured":"Wigerblad G, Cao Q, Brooks S, et al. Single-cell analysis reveals the range of transcriptional states of circulating human neutrophils. J Immunol. 2022;209(4):772\u201382. https:\/\/doi.org\/10.4049\/jimmunol.2200154.","journal-title":"J Immunol"},{"issue":"2","key":"4396_CR20","doi-asserted-by":"publisher","DOI":"10.21037\/cco-22-121","volume":"12","author":"AS McLaren","year":"2023","unstructured":"McLaren AS, Fetit R, Wood CS, et al. Single cell sequencing of neutrophils demonstrates phenotypic heterogeneity and functional plasticity in health, disease, and cancer. Chin Clin Oncol. 2023;12(2):18. https:\/\/doi.org\/10.21037\/cco-22-121.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"4396_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112525","volume":"42","author":"TS Kapellos","year":"2023","unstructured":"Kapellos TS, Ba\u00dfler K, Fujii W, et al. Systemic alterations in neutrophils and their precursors in early-stage chronic obstructive pulmonary disease. Cell Rep. 2023;42(6):112525. https:\/\/doi.org\/10.1016\/j.celrep.2023.112525.","journal-title":"Cell Rep"},{"issue":"2","key":"4396_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jaci.2025.04.011","volume":"156","author":"B Mariotti","year":"2025","unstructured":"Mariotti B, Bracaglia C, Gasperini S, et al. Innate immune reprogramming in circulating neutrophils of COPD patients. J Allergy Clin Immunol. 2025;156(2):373\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2025.04.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"4396_CR23","first-page":"3431","volume":"127","author":"J Lahoz-Beneytez","year":"2016","unstructured":"Lahoz-Beneytez J, Elemans M, Zhang Y, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood, J American Soc Hematol. 2016;127(26):3431\u20138.","journal-title":"Blood, J American Soc Hematol"},{"issue":"21","key":"4396_CR24","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","volume":"186","author":"RR Maas","year":"2023","unstructured":"Maas RR, Soukup K, Fournier N, et al. The local microenvironment drives activation of neutrophils in human brain tumors. Cell. 2023;186(21):4546-66. e27.","journal-title":"Cell"},{"issue":"1","key":"4396_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s44321-023-00013-x","volume":"16","author":"A Bodac","year":"2024","unstructured":"Bodac A, Mayet A, Rana S, et al. Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth. EMBO Mol Med. 2024;16(1):158\u201384.","journal-title":"EMBO Mol Med"},{"key":"4396_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708770","author":"AC Mihaila","year":"2021","unstructured":"Mihaila AC, Ciortan L, Macarie RD, et al. Transcriptional Profiling and Functional Analysis of N1\/N2 Neutrophils Reveal an Immunomodulatory Effect of S100A9-Blockade on the Pro-Inflammatory N1 Subpopulation. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.708770.","journal-title":"Front Immunol"},{"issue":"6","key":"4396_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu Y, Ma J, Yang X, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024;187(6):1422-39.e24. https:\/\/doi.org\/10.1016\/j.cell.2024.02.005.","journal-title":"Cell"},{"issue":"1","key":"4396_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Shen G, Zhou X, et al. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther. 2025;10(1):178. https:\/\/doi.org\/10.1038\/s41392-025-02242-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4396_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.06.004","volume":"82","author":"H Piccard","year":"2012","unstructured":"Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol. 2012;82(3):296\u2013309. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.06.004.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4396_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.13176","volume":"314","author":"BB Antuamwine","year":"2023","unstructured":"Antuamwine BB, Bosnjakovic R, Hofmann-Vega F, et al. N1 versus N2 and PMN-MDSC: A critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol Rev. 2023;314(1):250\u201379. https:\/\/doi.org\/10.1111\/imr.13176.","journal-title":"Immunol Rev"},{"issue":"9","key":"4396_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41590-020-0736-z","volume":"21","author":"X Xie","year":"2020","unstructured":"Xie X, Shi Q, Wu P, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol. 2020;21(9):1119\u201333. https:\/\/doi.org\/10.1038\/s41590-020-0736-z.","journal-title":"Nat Immunol"},{"issue":"17","key":"4396_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174261","volume":"13","author":"P Mart\u00ednez-Sanz","year":"2021","unstructured":"Mart\u00ednez-Sanz P, Hoogendijk AJ, Verkuijlen P, et al. CD47-SIRP\u03b1 checkpoint inhibition enhances neutrophil-mediated killing of Dinutuximab-opsonized Neuroblastoma cells. Cancers (Basel). 2021;13(17):4261. https:\/\/doi.org\/10.3390\/cancers13174261.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4396_CR33","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"3","key":"4396_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ccr.2011.08.012","volume":"20","author":"Z Granot","year":"2011","unstructured":"Granot Z, Henke E, Comen EA, et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300\u201314. https:\/\/doi.org\/10.1016\/j.ccr.2011.08.012.","journal-title":"Cancer Cell"},{"issue":"3","key":"4396_CR35","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati L, Kourtzelis I, Schulte-Schrepping J, et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-85. e12.","journal-title":"Cell"},{"issue":"11","key":"4396_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111473","volume":"17","author":"S Gallo","year":"2024","unstructured":"Gallo S, Folco CB, Crepaldi T. The MET oncogene: an update on targeting strategies. Pharmaceuticals Basel. 2024;17(11):1473. https:\/\/doi.org\/10.3390\/ph17111473.","journal-title":"Pharmaceuticals Basel"},{"issue":"7556","key":"4396_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14407","volume":"522","author":"V Finisguerra","year":"2015","unstructured":"Finisguerra V, Di Conza G, Di Matteo M, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522(7556):349\u201353. https:\/\/doi.org\/10.1038\/nature14407.","journal-title":"Nature"},{"issue":"2","key":"4396_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","volume":"41","author":"IL Linde","year":"2023","unstructured":"Linde IL, Prestwood TR, Qiu J, et al. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023;41(2):356-72.e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.002.","journal-title":"Cancer Cell"},{"key":"4396_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8064","volume":"6","author":"SR Satpathy","year":"2015","unstructured":"Satpathy SR, Jala VR, Bodduluri SR, et al. Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth. Nat Commun. 2015;6:7064. https:\/\/doi.org\/10.1038\/ncomms8064.","journal-title":"Nat Commun"},{"issue":"12","key":"4396_CR40","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui C, Chakraborty K, Tang XA, et al. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021;184(12):3163-77.e21. https:\/\/doi.org\/10.1016\/j.cell.2021.04.016.","journal-title":"Cell"},{"key":"4396_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111171","author":"E Pylaeva","year":"2022","unstructured":"Pylaeva E, Korschunow G, Spyra I, et al. During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2022.111171.","journal-title":"Cell Rep"},{"issue":"1","key":"4396_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","volume":"30","author":"S Singhal","year":"2016","unstructured":"Singhal S, Bhojnagarwala PS, O\u2019Brien S, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30(1):120\u201335. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.001.","journal-title":"Cancer Cell"},{"issue":"12","key":"4396_CR43","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1172\/jci77053","volume":"124","author":"EB Eruslanov","year":"2014","unstructured":"Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466\u201380. https:\/\/doi.org\/10.1172\/jci77053.","journal-title":"J Clin Invest"},{"issue":"2","key":"4396_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cell.2019.05.047","volume":"178","author":"A Ponzetta","year":"2019","unstructured":"Ponzetta A, Carriero R, Carnevale S, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178(2):346-60.e24. https:\/\/doi.org\/10.1016\/j.cell.2019.05.047.","journal-title":"Cell"},{"issue":"1","key":"4396_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou C, Gao Y, Ding P, et al. The role of CXCL family members in different diseases. Cell Death Discov. 2023;9(1):212.","journal-title":"Cell Death Discov"},{"key":"4396_CR46","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fimmu.2021.734188","volume":"12","author":"S SenGupta","year":"2021","unstructured":"SenGupta S, Hein LE, Parent CA. The Recruitment of Neutrophils to the Tumor Microenvironment Is Regulated by Multiple Mediators. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol"},{"issue":"19","key":"4396_CR47","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2217\/nnm-2020-0132","volume":"15","author":"L Taiarol","year":"2020","unstructured":"Taiarol L, Formicola B, Magro RD, et al. An update of nanoparticle-based approaches for glioblastoma multiforme immunotherapy. Nanomedicine Lond. 2020;15(19):1861\u201371.","journal-title":"Nanomedicine Lond"},{"key":"4396_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.actbio.2020.01.011","volume":"104","author":"V Naumenko","year":"2020","unstructured":"Naumenko V, Nikitin A, Garanina A, et al. Neutrophil-mediated transport is crucial for delivery of short-circulating magnetic nanoparticles to tumors. Acta Biomater. 2020;104:176\u201387. https:\/\/doi.org\/10.1016\/j.actbio.2020.01.011.","journal-title":"Acta Biomater"},{"issue":"11","key":"4396_CR49","doi-asserted-by":"publisher","first-page":"12599","DOI":"10.1021\/acsnano.9b03848","volume":"13","author":"VA Naumenko","year":"2019","unstructured":"Naumenko VA, Vlasova KY, Garanina AS, et al. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors. ACS Nano. 2019;13(11):12599\u2013612.","journal-title":"ACS Nano"},{"issue":"7","key":"4396_CR50","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nnano.2017.54","volume":"12","author":"J Xue","year":"2017","unstructured":"Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12(7):692\u2013700. https:\/\/doi.org\/10.1038\/nnano.2017.54.","journal-title":"Nat Nanotechnol"},{"key":"4396_CR51","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.actbio.2021.07.063","volume":"134","author":"J Ding","year":"2021","unstructured":"Ding J, Sui D, Liu M, et al. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil\/monocyte infiltration for tumor therapy. Acta Biomater. 2021;134:702\u201315. https:\/\/doi.org\/10.1016\/j.actbio.2021.07.063.","journal-title":"Acta Biomater"},{"issue":"16","key":"4396_CR52","doi-asserted-by":"publisher","first-page":"15542","DOI":"10.1021\/acsnano.3c02013","volume":"17","author":"Y Su","year":"2023","unstructured":"Su Y, Gao J, Dong X, et al. Neutrophil-mediated delivery of nanocrystal drugs via photoinduced inflammation enhances cancer therapy. ACS Nano. 2023;17(16):15542\u201355. https:\/\/doi.org\/10.1021\/acsnano.3c02013.","journal-title":"ACS Nano"},{"issue":"1","key":"4396_CR53","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1080\/10717544.2018.1474973","volume":"25","author":"X Luo","year":"2018","unstructured":"Luo X, Hu L, Zheng H, et al. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly (sialic acid)\u2013octadecylamine conjugate for lung cancer treatment. Drug Delivery. 2018;25(1):1200\u201312.","journal-title":"Drug Delivery"},{"issue":"1","key":"4396_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14(1):2266. https:\/\/doi.org\/10.1038\/s41467-023-37872-4.","journal-title":"Nat Commun"},{"issue":"14","key":"4396_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202005709","volume":"33","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhang H, Gu J, et al. Engineered extracellular vesicles for cancer therapy. Adv Mater. 2021;33(14):2005709.","journal-title":"Adv Mater"},{"issue":"19","key":"4396_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang J, Gu J, Wang X, et al. Engineering and targeting neutrophils for cancer therapy. Adv Mater. 2024;36(19):2310318. https:\/\/doi.org\/10.1002\/adma.202310318.","journal-title":"Adv Mater"},{"key":"4396_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120784","volume":"273","author":"J Wang","year":"2021","unstructured":"Wang J, Tang W, Yang M, et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials. 2021;273:120784. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120784.","journal-title":"Biomaterials"},{"issue":"12","key":"4396_CR58","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/bloodadvances.2024014860","volume":"9","author":"P Lanuti","year":"2025","unstructured":"Lanuti P, Guardalupi F, Corradi G, et al. CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy. Blood Adv. 2025;9(12):2907\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2024014860.","journal-title":"Blood Adv"},{"issue":"1","key":"4396_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11407-0","volume":"53","author":"AA Mathew","year":"2026","unstructured":"Mathew AA, Raheja R, Ramalingam K. Redefining cell therapy: CAR-engineered innate immune cells to conquer solid and hematologic malignancies. Mol Biol Rep. 2026;53(1):254. https:\/\/doi.org\/10.1007\/s11033-025-11407-0.","journal-title":"Mol Biol Rep"},{"key":"4396_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1491282","volume":"12","author":"M Alidadi","year":"2024","unstructured":"Alidadi M, Barzgar H, Zaman M, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biol. 2024;12:1491282. https:\/\/doi.org\/10.3389\/fcell.2024.1491282.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4396_CR61","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s43018-025-01015-z","volume":"6","author":"O Tsahouridis","year":"2025","unstructured":"Tsahouridis O, Xu M, Song F, et al. The landscape of CAR-engineered innate immune cells for cancer immunotherapy. Nat Cancer. 2025;6(7):1145\u201356. https:\/\/doi.org\/10.1038\/s43018-025-01015-z.","journal-title":"Nat Cancer"},{"issue":"6679","key":"4396_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf6493","volume":"383","author":"MSF Ng","year":"2024","unstructured":"Ng MSF, Kwok I, Tan L, et al. Deterministic reprogramming of neutrophils within tumors. Science. 2024;383(6679):eadf6493. https:\/\/doi.org\/10.1126\/science.adf6493.","journal-title":"Science"},{"key":"4396_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/17534259251365803","volume":"31","author":"J Wang","year":"2025","unstructured":"Wang J, Deng T, Chen R, et al. Engineered neutrophil, an emerging immune therapeutic strategy. Innate Immun. 2025;31:17534259251365803. https:\/\/doi.org\/10.1177\/17534259251365803.","journal-title":"Innate Immun"},{"issue":"1","key":"4396_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01170-7","volume":"9","author":"M Alrehaili","year":"2025","unstructured":"Alrehaili M, Couto PS, Khalife R, et al. CAR-macrophages in solid tumors: promise, progress, and prospects. npj Precis Oncol. 2025;9(1):382. https:\/\/doi.org\/10.1038\/s41698-025-01170-7.","journal-title":"npj Precis Oncol"},{"issue":"26","key":"4396_CR65","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2016-03-700336","volume":"127","author":"J Lahoz-Beneytez","year":"2016","unstructured":"Lahoz-Beneytez J, Elemans M, Zhang Y, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood. 2016;127(26):3431\u20138. https:\/\/doi.org\/10.1182\/blood-2016-03-700336.","journal-title":"Blood"},{"issue":"1","key":"4396_CR66","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.161.1.375","volume":"161","author":"MR Roberts","year":"1998","unstructured":"Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161(1):375\u201384.","journal-title":"J Immunol"},{"issue":"16","key":"4396_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36386","volume":"10","author":"SJ Malavez-Cajigas","year":"2024","unstructured":"Malavez-Cajigas SJ, Marini-Martinez FI, Lacourt-Ventura M, et al. HL-60 cells as a valuable model to study LPS-induced neutrophil extracellular traps release. Heliyon. 2024;10(16):e36386. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36386.","journal-title":"Heliyon"},{"issue":"1","key":"4396_CR68","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41598-020-78854-6","volume":"11","author":"KA Babatunde","year":"2021","unstructured":"Babatunde KA, Wang X, Hopke A, et al. Chemotaxis and swarming in differentiated HL-60 neutrophil-like cells. Sci Rep. 2021;11(1):778. https:\/\/doi.org\/10.1038\/s41598-020-78854-6.","journal-title":"Sci Rep"},{"issue":"6","key":"4396_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1822","volume":"6","author":"Z He","year":"2023","unstructured":"He Z, Wilson A, Rich F, et al. Chromosomal instability and its effect on cell lines. Cancer Rep (Hoboken). 2023;6(6):e1822. https:\/\/doi.org\/10.1002\/cnr2.1822.","journal-title":"Cancer Rep (Hoboken)"},{"key":"4396_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2121-12-23","volume":"12","author":"VM Kavsan","year":"2011","unstructured":"Kavsan VM, Iershov AV, Balynska OV. Immortalized cells and one oncogene in malignant transformation: old insights on new explanation. BMC Cell Biol. 2011;12:23. https:\/\/doi.org\/10.1186\/1471-2121-12-23.","journal-title":"BMC Cell Biol"},{"issue":"4","key":"4396_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321221","volume":"20","author":"M Vafajoo","year":"2025","unstructured":"Vafajoo M, Shahidi M, Shahriyary F, et al. Resveratrol decreases extracellular traps (ETs) in acute promyelocytic leukemia (NB4) cells. PLoS ONE. 2025;20(4):e0321221. https:\/\/doi.org\/10.1371\/journal.pone.0321221.","journal-title":"PLoS ONE"},{"issue":"2","key":"4396_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297758","volume":"19","author":"SB Bhakta","year":"2024","unstructured":"Bhakta SB, Lundgren SM, Sesti BN, et al. Neutrophil-like cells derived from the HL-60 cell-line as a genetically-tractable model for neutrophil degranulation. PLoS ONE. 2024;19(2):e0297758. https:\/\/doi.org\/10.1371\/journal.pone.0297758.","journal-title":"PLoS ONE"},{"issue":"12","key":"4396_CR73","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.4049\/jimmunol.170.12.6273","volume":"170","author":"CH Woo","year":"2003","unstructured":"Woo CH, Yoo MH, You HJ, et al. Transepithelial migration of neutrophils in response to leukotriene B4 is mediated by a reactive oxygen species-extracellular signal-regulated kinase-linked cascade. J Immunol. 2003;170(12):6273\u20139. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6273.","journal-title":"J Immunol"},{"key":"4396_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-1-60761-198-1_11","volume":"571","author":"A Millius","year":"2009","unstructured":"Millius A, Weiner OD. Chemotaxis in neutrophil-like HL-60 cells. Methods Mol Biol. 2009;571:167\u201377. https:\/\/doi.org\/10.1007\/978-1-60761-198-1_11.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"4396_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0328717","volume":"20","author":"T Hornstein","year":"2025","unstructured":"Hornstein T, Unfried K. Differentiation of HL-60 cells into primed neutrophils for the evaluation of antiapoptotic effects of poorly soluble nanoparticles. PLoS ONE. 2025;20(7):e0328717. https:\/\/doi.org\/10.1371\/journal.pone.0328717.","journal-title":"PLoS ONE"},{"issue":"4","key":"4396_CR76","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1365-2141.2004.05081.x","volume":"126","author":"PH Miles","year":"2004","unstructured":"Miles PH, Simmons PJ, Whitty G, et al. Improved haematopoietic recovery following transplantation with ex vivo\u2010expanded mobilized blood cells. Br J Haematol. 2004;126(4):536\u201345.","journal-title":"Br J Haematol"},{"issue":"11","key":"4396_CR77","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/j.1537-2995.2006.01001.x","volume":"46","author":"JM Boiron","year":"2006","unstructured":"Boiron JM, Dazey B, Cailliot C, et al. Large\u2010scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long\u2010term engraftment capacity. Transfusion. 2006;46(11):1934\u201342.","journal-title":"Transfusion"},{"issue":"2","key":"4396_CR78","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2141.2000.02054.x","volume":"109","author":"M Hino","year":"2000","unstructured":"Hino M, Suzuki K, Yamane T, et al. Ex vivo expansion of mature human neutrophils with normal functions from purified peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol. 2000;109(2):314\u201321.","journal-title":"Br J Haematol"},{"issue":"7","key":"4396_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180832","volume":"12","author":"Z Jie","year":"2017","unstructured":"Jie Z, Zhang Y, Wang C, et al. Large-scale ex vivo generation of human neutrophils from cord blood CD34+ cells. PLoS ONE. 2017;12(7):e0180832. https:\/\/doi.org\/10.1371\/journal.pone.0180832.","journal-title":"PLoS ONE"},{"issue":"1","key":"4396_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05337-x","volume":"22","author":"CA Naveh","year":"2024","unstructured":"Naveh CA, Roberts K, Zakrzewski P, et al. Neutrophils cultured ex vivo from CD34+ stem cells are immature and genetically tractable. J Transl Med. 2024;22(1):526. https:\/\/doi.org\/10.1186\/s12967-024-05337-x.","journal-title":"J Transl Med"},{"issue":"26","key":"4396_CR81","first-page":"6584","volume":"113","author":"Y Yokoyama","year":"2009","unstructured":"Yokoyama Y, Suzuki T, Sakata-Yanagimoto M, et al. Derivation of functional mature neutrophils from human embryonic stem cells. Blood, J American Soc Hematol. 2009;113(26):6584\u201392.","journal-title":"Blood, J American Soc Hematol"},{"issue":"9","key":"4396_CR82","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1172\/JCI38591","volume":"119","author":"K-D Choi","year":"2009","unstructured":"Choi K-D, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell\u2013derived lin\u2013CD34+ CD43+ CD45+ progenitors. J Clin Invest. 2009;119(9):2818\u201329.","journal-title":"J Clin Invest"},{"issue":"1","key":"4396_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1634\/stemcells.2007-0980","volume":"27","author":"K Saeki","year":"2009","unstructured":"Saeki K, Saeki K, Nakahara M, et al. A feeder-free and efficient production of functional neutrophils from human embryonic stem cells. Stem cells. 2009;27(1):59\u201367.","journal-title":"Stem cells"},{"issue":"4","key":"4396_CR84","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376. https:\/\/doi.org\/10.1016\/j.cell.2006.07.024.","journal-title":"Cell"},{"issue":"5","key":"4396_CR85","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019.","journal-title":"Cell"},{"key":"4396_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155518","volume":"262","author":"C Tang","year":"2024","unstructured":"Tang C, Zhang Y. Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: a comprehensive review. Pathol Res Pract. 2024;262:155518. https:\/\/doi.org\/10.1016\/j.prp.2024.155518.","journal-title":"Pathol Res Pract"},{"key":"4396_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2026.105384","author":"F Zhu","year":"2026","unstructured":"Zhu F, Chen Z, Yu Y, et al. Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block. Exp Hematol. 2026. https:\/\/doi.org\/10.1016\/j.exphem.2026.105384.","journal-title":"Exp Hematol"},{"key":"4396_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378739","volume":"15","author":"J Huang","year":"2024","unstructured":"Huang J, Yang Q, Wang W. CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy. Front Immunol. 2024;15:1378739. https:\/\/doi.org\/10.3389\/fimmu.2024.1378739.","journal-title":"Front Immunol"},{"issue":"1","key":"4396_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01873-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Behdarvand Dehkordi F, Chehelgerdi M, et al. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Mol Cancer. 2023;22(1):189. https:\/\/doi.org\/10.1186\/s12943-023-01873-0.","journal-title":"Mol Cancer"},{"issue":"6","key":"4396_CR90","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/stem.2332","volume":"34","author":"CL Sweeney","year":"2016","unstructured":"Sweeney CL, Teng R, Wang H, et al. Molecular analysis of neutrophil differentiation from human induced pluripotent stem cells delineates the kinetics of key regulators of hematopoiesis. Stem Cells. 2016;34(6):1513\u201326. https:\/\/doi.org\/10.1002\/stem.2332.","journal-title":"Stem Cells"},{"issue":"10","key":"4396_CR91","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/labinvest.2017.56","volume":"97","author":"R Teshigawara","year":"2017","unstructured":"Teshigawara R, Cho J, Kameda M, et al. Mechanism of human somatic reprogramming to iPS cell. Lab Invest. 2017;97(10):1152\u20137. https:\/\/doi.org\/10.1038\/labinvest.2017.56.","journal-title":"Lab Invest"},{"issue":"6","key":"4396_CR92","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/stmcls\/sxac020","volume":"40","author":"MS Poetsch","year":"2022","unstructured":"Poetsch MS, Strano A, Guan K. Human induced pluripotent stem cells: from cell origin, genomic stability, and epigenetic memory to translational medicine. Stem Cells. 2022;40(6):546\u201355. https:\/\/doi.org\/10.1093\/stmcls\/sxac020.","journal-title":"Stem Cells"},{"issue":"2","key":"4396_CR93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12015-020-09956-x","volume":"16","author":"TS Khoo","year":"2020","unstructured":"Khoo TS, Jamal R, Abdul Ghani NA, et al. Retention of somatic memory associated with cell identity, age and metabolism in induced pluripotent stem (iPS) cells reprogramming. Stem Cell Rev Rep. 2020;16(2):251\u201361. https:\/\/doi.org\/10.1007\/s12015-020-09956-x.","journal-title":"Stem Cell Rev Rep"},{"key":"4396_CR94","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/7651_2021_387","volume":"2454","author":"S Neeman-Egozi","year":"2022","unstructured":"Neeman-Egozi S, Baskin P, Binah O. Methods for isolation and reprogramming of various somatic cell sources into iPSCs. Methods Mol Biol. 2022;2454:643\u201355. https:\/\/doi.org\/10.1007\/7651_2021_387.","journal-title":"Methods Mol Biol"},{"key":"4396_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759558","volume":"12","author":"R Netsrithong","year":"2021","unstructured":"Netsrithong R, Wattanapanitch M. Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells. Front Immunol. 2021;12:759558. https:\/\/doi.org\/10.3389\/fimmu.2021.759558.","journal-title":"Front Immunol"},{"issue":"2","key":"4396_CR96","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/sctm.20-0242","volume":"10","author":"BS Jha","year":"2021","unstructured":"Jha BS, Farnoodian M, Bharti K. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl Med. 2021;10(2):198\u2013208. https:\/\/doi.org\/10.1002\/sctm.20-0242.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"4396_CR97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.stem.2013.11.005","volume":"14","author":"R Le","year":"2014","unstructured":"Le R, Kou Z, Jiang Y, et al. Enhanced telomere rejuvenation in pluripotent cells reprogrammed via nuclear transfer relative to induced pluripotent stem cells. Cell Stem Cell. 2014;14(1):27\u201339. https:\/\/doi.org\/10.1016\/j.stem.2013.11.005.","journal-title":"Cell Stem Cell"},{"issue":"14","key":"4396_CR98","doi-asserted-by":"publisher","first-page":"9767","DOI":"10.1074\/jbc.M112.403881","volume":"288","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wei X, Wang M, et al. Proliferation rate of somatic cells affects reprogramming efficiency. J Biol Chem. 2013;288(14):9767\u201378. https:\/\/doi.org\/10.1074\/jbc.M112.403881.","journal-title":"J Biol Chem"},{"issue":"5858","key":"4396_CR99","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Sci. 2007;318(5858):1917\u201320. https:\/\/doi.org\/10.1126\/science.1151526.","journal-title":"Sci"},{"issue":"32","key":"4396_CR100","doi-asserted-by":"publisher","first-page":"14152","DOI":"10.1073\/pnas.1009374107","volume":"107","author":"M Nakagawa","year":"2010","unstructured":"Nakagawa M, Takizawa N, Narita M, et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A. 2010;107(32):14152\u20137. https:\/\/doi.org\/10.1073\/pnas.1009374107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4396_CR101","doi-asserted-by":"publisher","first-page":"18","DOI":"10.32607\/20758251-2010-2-2-18-27","volume":"2","author":"SP Medvedev","year":"2010","unstructured":"Medvedev SP, Shevchenko AI, Zakian SM. Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine. Acta Naturae. 2010;2(2):18\u201328.","journal-title":"Acta Naturae"},{"issue":"9","key":"4396_CR102","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.ymthe.2021.08.013","volume":"29","author":"A Schambach","year":"2021","unstructured":"Schambach A, Morgan M, Fehse B. Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy. Mol Ther. 2021;29(9):2631\u20133. https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.013.","journal-title":"Mol Ther"},{"issue":"6","key":"4396_CR103","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392(6):577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"key":"4396_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat Y, Viktor P, Amajd A, et al. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci. 2024;348:122683. https:\/\/doi.org\/10.1016\/j.lfs.2024.122683.","journal-title":"Life Sci"},{"issue":"2","key":"4396_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14712590903455989","volume":"10","author":"L Shao","year":"2010","unstructured":"Shao L, Wu WS. Gene-delivery systems for iPS cell generation. Expert Opin Biol Ther. 2010;10(2):231\u201342. https:\/\/doi.org\/10.1517\/14712590903455989.","journal-title":"Expert Opin Biol Ther"},{"key":"4396_CR106","doi-asserted-by":"publisher","first-page":"1050856","DOI":"10.3389\/fcell.2022.1050856","volume":"10","author":"Z Karami","year":"2022","unstructured":"Karami Z, Moradi S, Eidi A, et al. Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research. Front Cell Dev Biol. 2022;10:1050856. https:\/\/doi.org\/10.3389\/fcell.2022.1050856.","journal-title":"Front Cell Dev Biol"},{"issue":"34","key":"4396_CR107","doi-asserted-by":"publisher","first-page":"14234","DOI":"10.1073\/pnas.1103509108","volume":"108","author":"H Ban","year":"2011","unstructured":"Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A. 2011;108(34):14234\u20139. https:\/\/doi.org\/10.1073\/pnas.1103509108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4396_CR108","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41434-019-0058-7","volume":"26","author":"Q Wang","year":"2019","unstructured":"Wang Q, Vossen A, Ikeda Y, et al. Measles vector as a multigene delivery platform facilitating iPSC reprogramming. Gene Ther. 2019;26(5):151\u201364. https:\/\/doi.org\/10.1038\/s41434-019-0058-7.","journal-title":"Gene Ther"},{"issue":"1","key":"4396_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0112-3","volume":"6","author":"AM Drozd","year":"2015","unstructured":"Drozd AM, Walczak MP, Piaskowski S, et al. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP\/EBNA-1 episomal reprogramming system. Stem Cell Res Ther. 2015;6(1):122. https:\/\/doi.org\/10.1186\/s13287-015-0112-3.","journal-title":"Stem Cell Res Ther"},{"key":"4396_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101710","author":"N Seyed","year":"2022","unstructured":"Seyed N, Zahedifard F, Habibzadeh S, et al. Antibiotic-free nanoplasmids as promising alternatives for conventional DNA vectors. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10101710.","journal-title":"Vaccines"},{"issue":"1","key":"4396_CR111","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nprot.2010.173","volume":"6","author":"KH Narsinh","year":"2011","unstructured":"Narsinh KH, Jia F, Robbins RC, et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc. 2011;6(1):78\u201388. https:\/\/doi.org\/10.1038\/nprot.2010.173.","journal-title":"Nat Protoc"},{"key":"4396_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1050856","author":"Z Karami","year":"2023","unstructured":"Karami Z, Moradi S, Eidi A, et al. Induced pluripotent stem cells: generation methods and a new perspective in COVID-19 research. Front Cell Dev Biol. 2023. https:\/\/doi.org\/10.3389\/fcell.2022.1050856.","journal-title":"Front Cell Dev Biol"},{"key":"4396_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060940","author":"E Pascale","year":"2022","unstructured":"Pascale E, Caiazza C, Paladino M, et al. MicroRNA roles in cell reprogramming mechanisms. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11060940.","journal-title":"Cells"},{"issue":"6","key":"4396_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060940","volume":"11","author":"E Pascale","year":"2022","unstructured":"Pascale E, Caiazza C, Paladino M, et al. MicroRNA roles in cell reprogramming mechanisms. Cells. 2022;11(6):940.","journal-title":"Cells"},{"issue":"5","key":"4396_CR115","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.stem.2009.04.005","volume":"4","author":"H Zhou","year":"2009","unstructured":"Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4(5):381\u20134. https:\/\/doi.org\/10.1016\/j.stem.2009.04.005.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"4396_CR116","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.stem.2009.05.005","volume":"4","author":"D Kim","year":"2009","unstructured":"Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4(6):472\u20136. https:\/\/doi.org\/10.1016\/j.stem.2009.05.005.","journal-title":"Cell Stem Cell"},{"key":"4396_CR117","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/453185","author":"Y Yang","year":"2012","unstructured":"Yang Y, Liu B, Dong J, et al. Proteins reprogramming: present and future. Scient World J. 2012. https:\/\/doi.org\/10.1100\/2012\/453185.","journal-title":"Scient World J"},{"key":"4396_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.911614","author":"B Son","year":"2022","unstructured":"Son B, Yoon H, Ryu J, et al. Enhanced efficiency of generating human-induced pluripotent stem cells using Lin28-30Kc19 fusion protein. Front Bioeng Biotechnol. 2022. https:\/\/doi.org\/10.3389\/fbioe.2022.911614.","journal-title":"Front Bioeng Biotechnol"},{"issue":"19","key":"4396_CR119","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00018-017-2586-x","volume":"74","author":"H Qin","year":"2017","unstructured":"Qin H, Zhao A, Fu X. Small molecules for reprogramming and transdifferentiation. Cell Mol Life Sci. 2017;74(19):3553\u201375. https:\/\/doi.org\/10.1007\/s00018-017-2586-x.","journal-title":"Cell Mol Life Sci"},{"issue":"6146","key":"4396_CR120","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1126\/science.1239278","volume":"341","author":"P Hou","year":"2013","unstructured":"Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651\u20134. https:\/\/doi.org\/10.1126\/science.1239278.","journal-title":"Science"},{"issue":"5","key":"4396_CR121","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41580-025-00836-1","volume":"26","author":"Y Wang","year":"2025","unstructured":"Wang Y, Cheng L. Improving chemical reprogramming strategies. Nat Rev Mol Cell Biol. 2025;26(5):333. https:\/\/doi.org\/10.1038\/s41580-025-00836-1.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"4396_CR122","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/rme-2018-0095","volume":"13","author":"S Sullivan","year":"2018","unstructured":"Sullivan S, Stacey GN, Akazawa C, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13(7):859\u201366. https:\/\/doi.org\/10.2217\/rme-2018-0095.","journal-title":"Regen Med"},{"issue":"6","key":"4396_CR123","doi-asserted-by":"publisher","first-page":"686","DOI":"10.5966\/sctm.2013-0158","volume":"3","author":"C Steichen","year":"2014","unstructured":"Steichen C, Luce E, Maluenda J, et al. Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity. Stem Cells Transl Med. 2014;3(6):686\u201391. https:\/\/doi.org\/10.5966\/sctm.2013-0158.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"4396_CR124","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12015-016-9662-8","volume":"12","author":"BA Baghbaderani","year":"2016","unstructured":"Baghbaderani BA, Syama A, Sivapatham R, et al. Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications. Stem Cell Rev Rep. 2016;12(4):394\u2013420. https:\/\/doi.org\/10.1007\/s12015-016-9662-8.","journal-title":"Stem Cell Rev Rep"},{"issue":"6","key":"4396_CR125","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","volume":"38","author":"M Sadeqi Nezhad","year":"2021","unstructured":"Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, et al. Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharm Res. 2021;38(6):931\u201345. https:\/\/doi.org\/10.1007\/s11095-021-03067-z.","journal-title":"Pharm Res"},{"key":"4396_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388475","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, et al. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14:1388475. https:\/\/doi.org\/10.3389\/fonc.2024.1388475.","journal-title":"Front Oncol"},{"issue":"3","key":"4396_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111128","volume":"40","author":"Y Chang","year":"2022","unstructured":"Chang Y, Syahirah R, Wang X, et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 2022;40(3):111128. https:\/\/doi.org\/10.1016\/j.celrep.2022.111128.","journal-title":"Cell Rep"},{"key":"4396_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.regen.2023.100074","author":"JD Harris","year":"2023","unstructured":"Harris JD, Chang Y, Syahirah R, et al. Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells. J Immunol Regen Med. 2023. https:\/\/doi.org\/10.1016\/j.regen.2023.100074.","journal-title":"J Immunol Regen Med"},{"issue":"16","key":"4396_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161248","volume":"14","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhou H, Xia X, et al. Hypoimmunogenic human iPSCs for repair and regeneration in the CNS. Cells. 2025;14(16):1248.","journal-title":"Cells"},{"issue":"3","key":"4396_CR130","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37(3):252\u20138. https:\/\/doi.org\/10.1038\/s41587-019-0016-3.","journal-title":"Nat Biotechnol"},{"key":"4396_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2025.104762","volume":"146","author":"AH Ismail","year":"2025","unstructured":"Ismail AH, Khormi MA, Mawkili W, et al. Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies. Exp Hematol. 2025;146:104762. https:\/\/doi.org\/10.1016\/j.exphem.2025.104762.","journal-title":"Exp Hematol"},{"issue":"10","key":"4396_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107804","volume":"26","author":"TC Harper","year":"2023","unstructured":"Harper TC, Oberlick EM, Smith TJ, et al. GATA1 deletion in human pluripotent stem cells increases differentiation yield and maturity of neutrophils. iScience. 2023;26(10):107804. https:\/\/doi.org\/10.1016\/j.isci.2023.107804.","journal-title":"iScience"},{"issue":"2","key":"4396_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012654","volume":"21","author":"AS Wagner","year":"2025","unstructured":"Wagner AS, Smith FM, Bennin DA, et al. GATA1-deficient human pluripotent stem cells generate neutrophils with improved antifungal immunity that is mediated by the integrin CD18. PLoS Pathog. 2025;21(2):e1012654. https:\/\/doi.org\/10.1371\/journal.ppat.1012654.","journal-title":"PLoS Pathog"},{"issue":"6","key":"4396_CR134","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/sctm.18-0255","volume":"8","author":"LR Trump","year":"2019","unstructured":"Trump LR, Nayak RC, Singh AK, et al. Neutrophils derived from genetically modified human induced pluripotent stem cells circulate and phagocytose bacteria in vivo. Stem Cells Transl Med. 2019;8(6):557\u201367. https:\/\/doi.org\/10.1002\/sctm.18-0255.","journal-title":"Stem Cells Transl Med"},{"key":"4396_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2023.104137","author":"T Hino","year":"2024","unstructured":"Hino T, Nakahara F, Miyauchi M, et al. AKT2 inhibition accelerates the acquisition of phagocytic ability in induced pluripotent stem cell\u2013derived neutrophils. Exp Hematol. 2024. https:\/\/doi.org\/10.1016\/j.exphem.2023.104137.","journal-title":"Exp Hematol"},{"issue":"1","key":"4396_CR136","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/jleuko\/qiae039","volume":"116","author":"MA Giese","year":"2024","unstructured":"Giese MA, Bennin DA, Schoen TJ, et al. PTP1B phosphatase dampens iPSC-derived neutrophil motility and antimicrobial function. J Leukoc Biol. 2024;116(1):118\u201331. https:\/\/doi.org\/10.1093\/jleuko\/qiae039.","journal-title":"J Leukoc Biol"},{"key":"4396_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156543","volume":"139","author":"W Zhao","year":"2025","unstructured":"Zhao W, Liu X, Tang J, et al. Jinkui Shenqi decoction targets PAD4 to restrain netosis and ameliorates psoriasis progression. Phytomedicine. 2025;139:156543. https:\/\/doi.org\/10.1016\/j.phymed.2025.156543.","journal-title":"Phytomedicine"},{"issue":"1","key":"4396_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-02676-7","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Li T, Chen H, et al. Role and intervention of PAD4 in NETs in acute respiratory distress syndrome. Respir Res. 2024;25(1):63. https:\/\/doi.org\/10.1186\/s12931-024-02676-7.","journal-title":"Respir Res"},{"key":"4396_CR139","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","volume":"74","author":"AC Sahillioglu","year":"2022","unstructured":"Sahillioglu AC, Schumacher TN. Safety switches for adoptive cell therapy. Curr Opin Immunol. 2022;74:190\u20138. https:\/\/doi.org\/10.1016\/j.coi.2021.07.002.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"4396_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s13619-023-00175-6","volume":"12","author":"H Zheng","year":"2023","unstructured":"Zheng H, Chen Y, Luo Q, et al. Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges. Cell Regen. 2023;12(1):31. https:\/\/doi.org\/10.1186\/s13619-023-00175-6.","journal-title":"Cell Regen"},{"issue":"2","key":"4396_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100075","volume":"1","author":"A Majumder","year":"2020","unstructured":"Majumder A, Suknuntha K, Bennin D, et al. Generation of human neutrophils from induced pluripotent stem cells in chemically defined conditions using ETV2 modified mRNA. STAR Protoc. 2020;1(2):100075. https:\/\/doi.org\/10.1016\/j.xpro.2020.100075.","journal-title":"STAR Protoc"},{"issue":"5","key":"4396_CR142","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3324\/haematol.2019.228064","volume":"106","author":"M Ackermann","year":"2021","unstructured":"Ackermann M, Haake K, Kempf H, et al. A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification. Haematologica. 2021;106(5):1354\u201367. https:\/\/doi.org\/10.3324\/haematol.2019.228064.","journal-title":"Haematologica"},{"issue":"1","key":"4396_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03785-2","volume":"15","author":"M Ackermann","year":"2024","unstructured":"Ackermann M, Saleh F, Abdin SM, et al. Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions. Stem Cell Res Ther. 2024;15(1):171. https:\/\/doi.org\/10.1186\/s13287-024-03785-2.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4396_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017565","volume":"6","author":"S Mukherjee","year":"2011","unstructured":"Mukherjee S, Santilli G, Blundell MP, et al. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS ONE. 2011;6(3):e17565. https:\/\/doi.org\/10.1371\/journal.pone.0017565.","journal-title":"PLoS ONE"},{"issue":"5","key":"4396_CR145","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jcp.22456","volume":"226","author":"T Morishima","year":"2011","unstructured":"Morishima T, Watanabe K, Niwa A, et al. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol. 2011;226(5):1283\u201391. https:\/\/doi.org\/10.1002\/jcp.22456.","journal-title":"J Cell Physiol"},{"issue":"8","key":"4396_CR146","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1073\/pnas.1217039110","volume":"110","author":"T Hiramoto","year":"2013","unstructured":"Hiramoto T, Ebihara Y, Mizoguchi Y, et al. Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells. Proc Natl Acad Sci U S A. 2013;110(8):3023\u20138. https:\/\/doi.org\/10.1073\/pnas.1217039110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4396_CR147","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/biores.2014.0045","volume":"3","author":"J Brault","year":"2014","unstructured":"Brault J, Goutagny E, Telugu N, et al. Optimized Generation of Functional Neutrophils and Macrophages from Patient-Specific Induced Pluripotent Stem Cells: Ex Vivo Models of X(0)-Linked, AR22(0)- and AR47(0)- Chronic Granulomatous Diseases. Biores Open Access. 2014;3(6):311\u201326. https:\/\/doi.org\/10.1089\/biores.2014.0045.","journal-title":"Biores Open Access"},{"key":"4396_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.46","volume":"2","author":"HT Lin","year":"2015","unstructured":"Lin HT, Masaki H, Yamaguchi T, et al. An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Mol Ther Methods Clin Dev. 2015;2:15046. https:\/\/doi.org\/10.1038\/mtm.2015.46.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4396_CR149","doi-asserted-by":"publisher","DOI":"10.19185\/matters.201805000005","author":"W Haenseler","year":"2018","unstructured":"Haenseler W, Kuzmenko E, Smalls-Mantey A, et al. Lentiviral gene therapy vector with UCOE stably restores function in iPSC-derived neutrophils of a CDG patient. Matters (Zur). 2018. https:\/\/doi.org\/10.19185\/matters.201805000005.","journal-title":"Matters (Zur)"},{"issue":"3","key":"4396_CR150","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3324\/haematol.2019.221804","volume":"105","author":"M Nasri","year":"2020","unstructured":"Nasri M, Ritter M, Mir P, et al. CRISPR\/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients. Haematologica. 2020;105(3):598\u2013609. https:\/\/doi.org\/10.3324\/haematol.2019.221804.","journal-title":"Haematologica"},{"issue":"1","key":"4396_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s13619-025-00254-w","volume":"14","author":"X Hu","year":"2025","unstructured":"Hu X, Kang B, Wang M, et al. Correction: human induced pluripotent stem cells derived neutrophils display strong anti-microbial potencies. Cell Regen. 2025;14(1):31. https:\/\/doi.org\/10.1186\/s13619-025-00254-w.","journal-title":"Cell Regen"},{"issue":"Supplement 1","key":"4396_CR152","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2024-205135","volume":"144","author":"A Majumder","year":"2024","unstructured":"Majumder A, Kabir ME, Jung HS, et al. iPSC-derived CAR neutrophils possess potent activity against solid tumors in vivo. Blood. 2024;144(Supplement 1):86. https:\/\/doi.org\/10.1182\/blood-2024-205135.","journal-title":"Blood"},{"key":"4396_CR153","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/jir.S284941","volume":"14","author":"M Blanter","year":"2021","unstructured":"Blanter M, Gouwy M, Struyf S. Studying neutrophil function in vitro: cell models and environmental factors. J Inflamm Res. 2021;14:141\u201362. https:\/\/doi.org\/10.2147\/jir.S284941.","journal-title":"J Inflamm Res"},{"issue":"8","key":"4396_CR154","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jcyt.2024.03.483","volume":"26","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Motaghi M, Patra SK, et al. Neutrophil generation from hematopoietic progenitor cells and induced pluripotent stem cells (iPSCs): potential applications. Cytotherapy. 2024;26(8):797\u2013805. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.483.","journal-title":"Cytotherapy"},{"issue":"24","key":"4396_CR155","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1182\/blood.2021011576","volume":"138","author":"M Miyauchi","year":"2021","unstructured":"Miyauchi M, Ito Y, Nakahara F, et al. Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment. Blood. 2021;138(24):2555\u201369. https:\/\/doi.org\/10.1182\/blood.2021011576.","journal-title":"Blood"},{"issue":"5","key":"4396_CR156","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41592-024-02172-2","volume":"21","author":"S Frenz-Wiessner","year":"2024","unstructured":"Frenz-Wiessner S, Fairley SD, Buser M, et al. Generation of complex bone marrow organoids from human induced pluripotent stem cells. Nat Methods. 2024;21(5):868\u201381. https:\/\/doi.org\/10.1038\/s41592-024-02172-2.","journal-title":"Nat Methods"},{"key":"4396_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720501","volume":"11","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, et al. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front Oncol. 2021;11:2021. https:\/\/doi.org\/10.3389\/fonc.2021.720501.","journal-title":"Front Oncol"},{"key":"4396_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang T, Bei C, Hu Z, et al. CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 2024;12:2024. https:\/\/doi.org\/10.3389\/fcell.2024.1464218.","journal-title":"Front Cell Dev Biol"},{"key":"4396_CR159","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36688","volume":"7","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7:e36688. https:\/\/doi.org\/10.7554\/eLife.36688.","journal-title":"Elife"},{"key":"4396_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557644","volume":"16","author":"J Han","year":"2025","unstructured":"Han J, Wang Y, Chan GC-F, et al. Designs of NKG2D-based immunotherapeutics for cancer. Front Immunol. 2025;16:2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1557644.","journal-title":"Front Immunol"},{"issue":"6","key":"4396_CR161","doi-asserted-by":"publisher","first-page":"517","DOI":"10.11406\/rinketsu.66.517","volume":"66","author":"T Hino","year":"2025","unstructured":"Hino T, Kurokawa M. [Development of a method for mass production of functional neutrophils derived from human induced pluripotent stem cells]. Rinsho Ketsueki. 2025;66(6):517\u201324. https:\/\/doi.org\/10.11406\/rinketsu.66.517.","journal-title":"Rinsho Ketsueki"},{"issue":"3","key":"4396_CR162","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","volume":"24","author":"A Montel-Hagen","year":"2019","unstructured":"Montel-Hagen A, Seet CS, Li S, et al. Organoid-induced differentiation of conventional T Cells from human pluripotent stem cells. Cell Stem Cell. 2019;24(3):376-89.e8. https:\/\/doi.org\/10.1016\/j.stem.2018.12.011.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"4396_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20658-3","volume":"12","author":"S Iriguchi","year":"2021","unstructured":"Iriguchi S, Yasui Y, Kawai Y, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12(1):430. https:\/\/doi.org\/10.1038\/s41467-020-20658-3.","journal-title":"Nat Commun"},{"key":"4396_CR164","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.omtm.2021.03.002","volume":"21","author":"H Mashima","year":"2021","unstructured":"Mashima H, Zhang R, Kobayashi T, et al. Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. Mol Ther Methods Clin Dev. 2021;21:171\u20139. https:\/\/doi.org\/10.1016\/j.omtm.2021.03.002.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4396_CR165","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2147\/bctt.S542787","volume":"17","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. N2 neutrophils and tumor progression in breast cancer: molecular pathways and implications. Breast Cancer (Dove Med Press). 2025;17:639\u201351. https:\/\/doi.org\/10.2147\/bctt.S542787.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"38","key":"4396_CR166","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300366120","volume":"120","author":"J Wu","year":"2023","unstructured":"Wu J, Wang X, Huang Y, et al. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proc Natl Acad Sci U S A. 2023;120(38):e2300366120. https:\/\/doi.org\/10.1073\/pnas.2300366120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4396_CR167","doi-asserted-by":"publisher","first-page":"465","DOI":"10.17305\/bb.2023.9675","volume":"24","author":"K Chen","year":"2024","unstructured":"Chen K, Liu ML, Wang JC, et al. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. Biomol Biomed. 2024;24(3):465\u201376. https:\/\/doi.org\/10.17305\/bb.2023.9675.","journal-title":"Biomol Biomed"},{"issue":"1","key":"4396_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10704","volume":"10","author":"N Kumbhojkar","year":"2025","unstructured":"Kumbhojkar N, Mitragotri S. Activated neutrophils: a next generation cellular immunotherapy. Bioeng Transl Med. 2025;10(1):e10704. https:\/\/doi.org\/10.1002\/btm2.10704.","journal-title":"Bioeng Transl Med"},{"issue":"4","key":"4396_CR169","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bj.2020.09.001","volume":"44","author":"SC Yang","year":"2021","unstructured":"Yang SC, Tsai YF, Pan YL, et al. Understanding the role of neutrophils in acute respiratory distress syndrome. Biomed J. 2021;44(4):439\u201346. https:\/\/doi.org\/10.1016\/j.bj.2020.09.001.","journal-title":"Biomed J"},{"key":"4396_CR170","doi-asserted-by":"publisher","first-page":"1511931","DOI":"10.3389\/fcell.2024.1511931","volume":"12","author":"F Dehghan","year":"2024","unstructured":"Dehghan F, Metanat Y, Askarizadeh M, et al. Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy. Front Cell Dev Biol. 2024;12:1511931. https:\/\/doi.org\/10.3389\/fcell.2024.1511931.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"4396_CR171","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.Ccr-23-1735","volume":"30","author":"AM Kieliszek","year":"2024","unstructured":"Kieliszek AM, Mobilio D, Upreti D, et al. Intratumoral delivery of chimeric antigen receptor T Cells targeting CD133 effectively treats brain metastases. Clin Cancer Res. 2024;30(3):554\u201363. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1735.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4396_CR172","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.synbio.2023.09.001","volume":"8","author":"J Cheng","year":"2023","unstructured":"Cheng J, Liu M, Zhang J. Intelligent tunable CAR-T cell therapy leads the new trend. Synth Syst Biotechnol. 2023;8(4):606\u20139. https:\/\/doi.org\/10.1016\/j.synbio.2023.09.001.","journal-title":"Synth Syst Biotechnol"},{"key":"4396_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.910908","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xu Z, Liu Z. Impact of Neutrophil Extracellular Traps on thrombosis formation: new findings and future perspective. Front Cell Infect Microbiol. 2022;12:910908. https:\/\/doi.org\/10.3389\/fcimb.2022.910908.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"4396_CR174","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.V130.Suppl_1.2268.2268","volume":"130","author":"K Gollomp","year":"2017","unstructured":"Gollomp K, Hayes V, Johnston I, et al. Inhibition of Neutrophil Extracellular Trap Release through the Disruption of PAD4 Leads to Decreased Neutrophil and Platelet Accumulation at Sites of Venular Vascular Injury in a Murine Model of Heparin-Induced Thrombocytopenia. Blood. 2017;130(1):2268. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2268.2268.","journal-title":"Blood"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04396-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:18Z","timestamp":1790160078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04396-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":174,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04396-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial registration number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}